Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.

Article Details

Citation
Copy to clipboard

Pellesi L, Guerzoni S, Pini LA

Spotlight on Anti-CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date.

Clin Pharmacol Drug Dev. 2017 Nov;6(6):534-547. doi: 10.1002/cpdd.345. Epub 2017 Apr 14.

PubMed ID
28409893 [ View in PubMed
]
Abstract

Migraine, a common neurovascular brain disorder, represents a severe and widespread health problem; along with medication-induced (medication-overuse) headache, it is the third-leading cause of disability worldwide. Currently, its therapeutic management remains unsatisfactory for several reasons; up to 40% of migraineurs are eligible for prophylactic treatment, but there are issues of efficacy, safety, and adherence. In recent years the evidence on the role of calcitonin gene-related peptide (CGRP) in migraine pathophysiology has been consolidated, so new and promising treatments for migraine pain and its possible prevention have been developed. The following review reports the results of the clinical trials conducted so far with each of the new monoclonal antibodies targeting CGRP or its receptor, with particular reference to safety, tolerance, and efficacy in migraine prevention. Moreover, the pharmacological characterization and further developments of each monoclonal antibody are reported, based on current knowledge.

DrugBank Data that Cites this Article

Drugs